UROTRACTIN ® is a pipemidic acid-based drug
THERAPEUTIC GROUP: Antibacterial for systemic use
Indications UROTRACTIN ® Pipemidic acid
UROTRACTIN ® is used in the clinical setting in the treatment of urinary tract infections caused by microorganisms sensitive to pipemidic acid.
The same drug has also been shown to be useful in the prophylaxis of post-operative and post-diagnostic urinary infections.
Mechanism of action UROTRACTIN ® Pipemidic acid
UROTRACTIN ® is a pipemidic acid-based drug, antibacterial listed among the first generation fluoroquinolones, effective in the treatment of urinary infections caused by sensitive Gram positive and Gram negative microorganisms.
Taken orally, pipemidic acid is rapidly absorbed from the gastrointestinal tract, is distributed in organs such as the kidney, prostate and intestine, concentrating in the urinary level following glomerular filtration.
It is precisely at this level that the active ingredient carries out its maximum therapeutic efficacy, permeating the membranes of bacterial cells and inhibiting enzymes involved in bacterial DNA replication mechanisms such as DNA-gyrases and DNA-topoisomerases, and thus controlling the proliferation and the spread of the pathogen.
The aforesaid mechanism of action, also extended to plasmid DNA, allows to control the spread of antibiotic resistance genes, thus maintaining a particularly high therapeutic sensitivity.
Studies carried out and clinical efficacy
PHOSPHOMYCIN VS PIPEMIDIC ACID IN THE TREATMENT OF INFECTIONS OF THE URINARY TRACT
Primary Aten. 1992 Dec; 10: 1007-12.
Single oral dose of phosphomycin trometamol versus pipemidic acid and norfloxacin in treating uncomplicated low-level urinary tract infections.
Cortés R, Pascual T, Lou Arnal S, Orozco F, Sunyer L.
Interesting study that compares the efficacy and safety of pipemidic acid and fosfomycin treatment in urinary infections, demonstrating how fosfomycin can be an equally effective drug in these cases.
ADVERSE REACTIONS TO PIPEMIDIC ACID
J Dermatol. 1991 Jan; 18: 59-60.
Fixed drug eruption due to pipemidic acid.
Miyagawa S, Yamashina Y, Hirota S, Shirai T.
Case report denouncing the appearance of hypersensitivity skin lesions during treatment with pipemidic acid in a 71-year-old patient.
PIPEMIDIC ACID AND RECURRING CYSTITIS
Ann Urol (Paris). 1989; 23: 53-7.
[Preventive treatment of recurrent essential cystitis in women. Comparative study of pipemidic acid and placebo in a daily dose of 200 mg. for 6 months].
Clinical trial conducted for several months on women suffering from recurrent cystitis which demonstrates the good efficacy and good degree of safety of pipemidic acid in the treatment of these often relapsing pathological conditions.
Method of use and dosage
UROTRACTIN ®
Hard capsules of 200 - 400 mg of pipemidic acid.
The dosage schedule useful for the treatment of urinary tract infections should be defined by the physician on the basis of the physio-pathological and clinical characteristics of the patient.
Generally, the assumption of 400 mg of pipemidic acid twice a day, preferably between meals, is sufficient to guarantee a prompt remission of the symptoms.
Warnings UROTRACTIN ® Pipemidic acid
The use of UROTRACTIN ® should be preceded by a careful medical examination aimed at evaluating the prescribing appropriateness and the possible presence of contraindications to the use of pipemidic acid.
During therapy with UROTRACTIN ® it is advisable to avoid direct exposure to ultraviolet radiation given the photosensitizing power of pipemidic acid, potentially responsible for burns and erythema.
PREGNANCY AND BREASTFEEDING
The use of UROTRACTIN ® during pregnancy should be limited to cases of real need and clearly under close medical supervision.
These limitations are imposed by the absence of studies capable of fully characterizing the safety profile of the drug for the health of the fetus.
Interactions
During therapy with UROTRACTIN ® it would be useful to avoid the simultaneous intake of preparations, foods and active ingredients containing divalent metals, such as magnesium, aluminum, calcium, iron and zinc, given the chelating capacity of the latter against pipemidic acid.
Different studies also show pharmacologically relevant interactions with erythromycin, glibenclamide, probenecid and H2 antagonists.
Contraindications UROTRACTIN ® Pipemidic acid
The use of UROTRACTIN ® is contraindicated in patients hypersensitive to the active substance or to any of its excipients.
Undesirable Effects - Side Effects
Pipemidic acid therapy could lead to nausea, vomiting, diarrhea, abdominal pain, dyspepsia and only rarely more serious side effects such as pseudomembranous colitis or dermatological and hepatotoxic adverse reactions.
Note
UROTRACTIN ® is a drug subject to mandatory medical prescription.
The information on UROTRACTIN ® Pipemidic acid published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
